

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

14-691/S-020

Chemistry Review(s)

Chemistry Review

To: NDA 14-691/SCS-020
From: Eric P Duffy, PhD, CMC Team Leader
Date: 05/15/01
Re: Team Leaders Addendum to CMC Review

The CMC review concluded that the supplement should be approved, with comment to the firm regard comparing the revised impurity peak area calculation to the previous to determine whether the revised lower reporting limit of — % (from —%) represented a change in the actual amount of impurity present. On further consideration, the TL has decided not to pursue the issue – if there were any change it would result in a lower actual amount of impurity.

If the firm agrees to make the labeling change requested by the Clinical Pharmacology reviewer, the supplement should be approved.

Eric P Duffy, PhD
Chemistry Team Leader
Division of Oncology Drug Products

C:/data/wordfiles/nda/14961_S020.1ed


**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Eric Duffy

5/15/01 01:39:21 PM

CHEMIST

CHEMIST'S REVIEW		1. ORGANIZATION HFD-150 DODP		2. NDA NUMBER 14-691	
3. NAME AND ADDRESS OF APPLICANT (City and State) GlaxoWellcome Inc. 5 Moore Dr. Research Triangle Park, N. Carolina 27709				4. AF NUMBER	
6. NAME OF DRUG Alkeran				7. NONPROPRIETARY NAME melphalan tablets	
8. SUPPLEMENT PROVIDES FOR: transfer the DP manufacturing site to Glaxo Wellcome Operations in Darford UK.				5. SUPPLEMENT (S) NUMBER(S) DATES(S) SCS 020 12-6-2000	
10. PHARMACOLOGICAL CATEGORY Antineoplastic				11. HOW DISPENSEDRX <input checked="" type="checkbox"/> OTC	
13. DOSAGE FORM(S) Tablets				14. POTENCY 2 mg/tablet	
15. CHEMICAL NAME AND STRUCTURE 4- [bis(2-chloroethyl) amino] -L-phenylalanine				12. RELATED IND/NDA/DMP None	
				16. RECORDS AND REPORTS CURRENT YES <input checked="" type="checkbox"/> NO <input type="checkbox"/> REVIEWED YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>	
17. COMMENTS See review note.					
18. CONCLUSIONS AND RECOMMENDATIONS The supplement is recommended for approval. However, the revision of the calculation for the related impurities in the DS is of concern. If the change is thought to be insignificant, the company should provide the test data to demonstrate that revision of the method for calculation of peak area which sets the lower reporting limit from current $\frac{1}{2}$ % to proposed $\frac{1}{4}$ % does not reduce the actual impurity level (individual and total) in the DS.					
NAME Chengyi Liang, Ph.D.			SIGNATURE		DATE COMPLETED 3-20-2001
<u>DISTRIBUTION</u>	ORIGINAL NDA	DIVISION FILE	Reviewer: C.Y. Liang HFD-150	CSO: M. Pelosi HFD-150	Chemistry Team Leader E. Duffy

REVIEW NOTE

Redacted 3

pages of trade

secret and/or

confidential

commercial

information

/s/

Chengyi Liang
3/30/01 08:03:04 AM
CHEMIST

Eric Duffy
4/3/01 12:31:57 PM
CHEMIST